Qian Jun, Jiang Bin, Li Min, Chen Juan, Fang Mingzhi
Department of Oncology, The Third Affiliated Hospital, Nanjing University of Traditional Chinese Medicine, No. 1 Jinling Road, Nanjing, Jiangsu, 210029, China.
World J Surg. 2013 Dec;37(12):2944-9. doi: 10.1007/s00268-013-2205-4.
MicroRNAs (miRNAs), small noncoding RNAs, have been reported to be highly involved in the formation and progression of all types of human cancer including colorectal cancer (CRC). Therefore, miRNAs are also potential prognostic biomarkers in CRC patients. The aim of this study was to detect the expression of miR-16 in human CRC tissues and investigate its clinicopathologic or prognostic significance.
TaqMan quantitative reverse transcription polymerase chain reaction (qRT-PCR) assay was performed to determine the expression of miR-16 in 143 primary CRC tissues and 18 corresponding normal colonic mucosa from patients who had undergone surgery. The association of miR-16 expression with clinicopathologic features of CRC patients was statistically analyzed. Kaplan-Meier analyses were used to assess patient survival. Univariate and multivariate Cox analyses were performed.
The relative level of miR-16 in 18 CRC tissues was significantly lower than that in corresponding normal colonic mucosa (p < 0.001). Statistical analyses revealed that the status of miR-16 expression was closely associated with tumor differentiation, lymph node metastasis, L category, V category, TNM stage, and tumor recurrence of CRC (p = 0.001, 0.003, 0.001, 0.005, 0.003, and 0.017, respectively). Kaplan-Meier analyses indicated that patients with low-miR-16 had lower 5-year overall survival than those with high-miR-16 (31.2 vs. 58.3 %; p = 0.0012). Multivariate Cox regression analyses indicated that the status of miR-16 expression might be an independent prognostic factor for CRC patients (hazard ratio 1.67; 95 % confidence interval 1.22-2.54; p = 0.018).
Down-regulation of miR-16 plays critical roles in CRC progression. Low miR-16 expression is an independent factor predicting a poor prognosis for CRC patients.
微小RNA（miRNA）是一类小的非编码RNA，据报道其高度参与包括结直肠癌（CRC）在内的所有类型人类癌症的形成和进展。因此，miRNA也是CRC患者潜在的预后生物标志物。本研究旨在检测miR-16在人CRC组织中的表达，并探讨其临床病理或预后意义。
采用TaqMan定量逆转录聚合酶链反应（qRT-PCR）检测143例原发性CRC组织及18例手术患者相应正常结肠黏膜中miR-16的表达。对miR-16表达与CRC患者临床病理特征的相关性进行统计学分析。采用Kaplan-Meier分析评估患者生存率。进行单因素和多因素Cox分析。
18例CRC组织中miR-16的相对水平显著低于相应正常结肠黏膜（p<0.001）。统计学分析显示，miR-16表达状态与CRC的肿瘤分化、淋巴结转移、L分类、V分类、TNM分期及肿瘤复发密切相关（p分别为0.001、0.003、0.001、0.005、0.003和0.017）。Kaplan-Meier分析表明，低miR-16患者的5年总生存率低于高miR-16患者（31.2%对58.3%；p = 0.0012）。多因素Cox回归分析表明，miR-16表达状态可能是CRC患者的独立预后因素（风险比1.67；95%置信区间1.22 - 2.54；p = 0.018）。
miR-16的下调在CRC进展中起关键作用。低miR-16表达是预测CRC患者预后不良的独立因素。
